AstraZeneca wins expanded indication for type 2 diabetes treatment Forxiga < Pharma < Article - KBR
AstraZeneca diabetes drug cuts complications | Financial Times
AstraZeneca's diabetes drug Farxiga fails in COVID-19 study - CGTN
AstraZeneca diabetes drug fails test in Covid trial | Business | The Times
EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study | Fierce Pharma
AstraZeneca Lifts Profit Guidance on Cancer, Diabetes Drugs - Bloomberg
Astrazeneca New Diabetes Drug | ESaral
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZVZAPQQPC5JM3BZWDORGE6CCFA.jpg "AstraZeneca's once-weekly diabetes drug gets U.S. nod for children | Reuters")
AstraZeneca's once-weekly diabetes drug gets U.S. nod for children | Reuters
Astrazeneca Forxiga Tablet, Dapagliflozin, Prescription, Treatment: Type 2 Diabetes Mellitus at Rs 800/strip in Nagpur
AstraZeneca posts data to show potential of diabetes drug in heart failure (NASDAQ:AZN) | Seeking Alpha
AstraZeneca's diabetes drug curbs heart failure, kidney risks, Health News, ET HealthWorld
AstraZeneca India Gets Approval To Market Anti-Diabetes Drug
AstraZeneca diabetes med Forxiga gains positive CHMP label extension recommendation | Seeking Alpha
AstraZeneca Sees Greater Potential for Top Heart Drug - Bloomberg
Sun Pharma, AstraZeneca tie up to sell latest anti-diabetes drug Dapagliflozin - The Economic Times
AstraZeneca diabetes drug shows promise in heart failure | Reuters
AZ launches combination diabetes drug in UK - PMLiVE
EMA accepts Marketing Authorisation for Forxiga in type-1 diabetes
Type 1 diabetes drug was withdrawn because of a “commercial conflict of interest,” charity argues | The BMJ
AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma
FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations | DAIC
AstraZeneca diabetes drug gets green light in EU
